What does DECURA PHARMA do?

DECURA PHARMA is a holding company in Oostende. Private Limited, started on 15 July 2009, 2 establishments.

What is the address of DECURA PHARMA?

The registered office of DECURA PHARMA is located at Gistelsesteenweg 18, 8400 Oostende.

Is DECURA PHARMA still active?

Yes. According to the CBE (29 October 2026) DECURA PHARMA is active, legal situation “Normale toestand”, started on 15 July 2009.

Is DECURA PHARMA registered on Peppol?

Yes, DECURA PHARMA is registered on the Peppol network with ID 0208:0817127010.

What is the enterprise number of DECURA PHARMA?

The enterprise number of DECURA PHARMA is BE0817127010.

When was DECURA PHARMA founded?

DECURA PHARMA was founded on 15 July 2009.

Who are the directors of DECURA PHARMA?

According to the 2025 annual accounts, the directors of DECURA PHARMA are: Ann Raes, Andy Decuypere.

Is DECURA PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 July 2009; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did DECURA PHARMA make in 2025?

DECURA PHARMA posted a profit after taxes of € 271,335 in financial year 2025.

What is the revenue of DECURA PHARMA?

As a small company, DECURA PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 635,995.

DECURA PHARMA (Private Limited) - Oostende - BE0817127010

Dossier DECURA PHARMA, printed on 29 October 2026 from databakkes.be/en/0817127010/decura-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 17 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

DECURA PHARMA from Oostende, company number BE0817127010, closed financial year 2025 with a result of € 271,335 after tax. For that financial year DECURA PHARMA recorded a gross margin of € 635,995 and equity of € 3.8 million. Compared with financial year 2024, the result moved from € 108,814 to € 271,335. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 30, 2025.

What it is worth Growing

€ 3.8 million

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 271,335

▲ 149% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 16,015

▼ 77% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 3.8 million.

People and assets in 2025

Vehicles and equipment

€ 26,831

▼ 36% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3.4 million

▲ 47% vs 2024

€ 529,935 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 526,188

▲ 166% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 88,328

▲ 17% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 622,093 Gross margin 2022: € 622,093 First fiscal year in the series	€ 578,746 Gross margin 2023: € 578,746 ▼ 7% vs 2022 (€ 622,093) Unfavourable step	€ 425,832 Gross margin 2024: € 425,832 ▼ 26% vs 2023 (€ 578,746) Unfavourable step	€ 635,995 Gross margin 2025: € 635,995 ▲ 49% vs 2024 (€ 425,832) Favourable step	▲ 49%
Profit after taxes	€ 283,336 Profit after taxes 2022: € 283,336 First fiscal year in the series	€ 234,659 Profit after taxes 2023: € 234,659 ▼ 17% vs 2022 (€ 283,336) Unfavourable step	€ 108,814 Profit after taxes 2024: € 108,814 ▼ 54% vs 2023 (€ 234,659) Unfavourable step	€ 271,335 Profit after taxes 2025: € 271,335 ▲ 149% vs 2024 (€ 108,814) Favourable step	▲ 149%
Equity	€ 3,417,226 Equity 2022: € 3,417,226 First fiscal year in the series	€ 3,551,885 Equity 2023: € 3,551,885 ▲ 4% vs 2022 (€ 3,417,226) Favourable step	€ 3,560,700 Equity 2024: € 3,560,700 Unchanged (€ 3,551,885) Favourable step	€ 3,832,035 Equity 2025: € 3,832,035 ▲ 8% vs 2024 (€ 3,560,700) Favourable step	▲ 8%
Total debts	€ 4,057,777 Total debts 2022: € 4,057,777 First fiscal year in the series	€ 4,524,685 Total debts 2023: € 4,524,685 ▲ 12% vs 2022 (€ 4,057,777) Unfavourable step	€ 5,069,083 Total debts 2024: € 5,069,083 ▲ 12% vs 2023 (€ 4,524,685) Unfavourable step	€ 6,895,462 Total debts 2025: € 6,895,462 ▲ 36% vs 2024 (€ 5,069,083) Unfavourable step	▲ 36%
Cash	€ 3,446 Cash 2022: € 3,446 First fiscal year in the series	€ 34,447 Cash 2023: € 34,447 ▲ € 31,001 vs 2022 (€ 3,446) Favourable step	€ 69,549 Cash 2024: € 69,549 ▲ 102% vs 2023 (€ 34,447) Favourable step	€ 16,015 Cash 2025: € 16,015 ▼ 77% vs 2024 (€ 69,549) Unfavourable step	▼ 77%
Land & buildings	€ 2,193,194 Land & buildings 2022: € 2,193,194 First fiscal year in the series	€ 2,652,165 Land & buildings 2023: € 2,652,165 ▲ 21% vs 2022 (€ 2,193,194) Unchanged	€ 2,562,082 Land & buildings 2024: € 2,562,082 ▼ 3% vs 2023 (€ 2,652,165) Unchanged	€ 2,464,155 Land & buildings 2025: € 2,464,155 ▼ 4% vs 2024 (€ 2,562,082) Unchanged	▼ 4%
Retained profit	€ 3,398,676 Retained profit 2022: € 3,398,676 First fiscal year in the series	€ 3,533,335 Retained profit 2023: € 3,533,335 ▲ 4% vs 2022 (€ 3,398,676) Favourable step	€ 3,542,150 Retained profit 2024: € 3,542,150 Unchanged (€ 3,533,335) Favourable step	€ 3,813,485 Retained profit 2025: € 3,813,485 ▲ 8% vs 2024 (€ 3,542,150) Favourable step	▲ 8%
Dividend	€ 100,000 Dividend 2022: € 100,000 First fiscal year in the series	€ 100,000 Dividend 2023: € 100,000 Unchanged (€ 100,000) Unchanged	€ 100,000 Dividend 2024: € 100,000 Unchanged (€ 100,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 100,000) Unchanged	▼ 100%
Bank debt	€ 2,205,105 Bank debt 2022: € 2,205,105 First fiscal year in the series	€ 1,930,249 Bank debt 2023: € 1,930,249 ▼ 12% vs 2022 (€ 2,205,105) Favourable step	€ 2,301,312 Bank debt 2024: € 2,301,312 ▲ 19% vs 2023 (€ 1,930,249) Unfavourable step	€ 3,376,130 Bank debt 2025: € 3,376,130 ▲ 47% vs 2024 (€ 2,301,312) Unfavourable step	▲ 47%
Balance sheet total	€ 7,661,290 Balance sheet total 2022: € 7,661,290 First fiscal year in the series	€ 8,251,895 Balance sheet total 2023: € 8,251,895 ▲ 8% vs 2022 (€ 7,661,290) Unchanged	€ 8,794,145 Balance sheet total 2024: € 8,794,145 ▲ 7% vs 2023 (€ 8,251,895) Unchanged	€ 10,880,897 Balance sheet total 2025: € 10,880,897 ▲ 24% vs 2024 (€ 8,794,145) Unchanged	▲ 24%

Key figures of DECURA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to DECURA PHARMA?

What happened at DECURA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 1, 2026 New establishment in Gent. KBO
Oct 30, 2025 New annual accounts for financial year 2025: profit of € 271,335 (▲ 149% vs 2024). Source: NBB ↗
Aug 26, 2009 New establishment in Oostende. KBO
Jul 15, 2009 Start of the company according to the CBE. KBO
2009 Ann Raes became a director. NBB
2009 Andy Decuypere became a director. NBB

In short

From € 283,336 profit in 2022 to € 271,335 profit in 2025.

Paid € 411,566 in corporate taxes since 2022.

Best year ever: 2022, with € 283,336 profit.

Paid out € 300,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Ann Raes

Andy Decuypere

DECURA PHARMA

Apotheek Raes 100%

Health And Beauty Shop 100%

Lindephar 100%

Deraphar 99.9%

Behind DECURA PHARMA are Ann Raes and Andy Decuypere. It owns 100% of Apotheek Raes, 100% of Health And Beauty Shop, 100% of Lindephar, 99.9% of Deraphar and 50% of Fidelmed itself.

Directors

According to the 2025 annual accounts

Ann Raes

Manager

Also active at: Deraphar, LINDEPHAR, APOTHEEK RAES

since 2009

Andy Decuypere

Manager

Also active at: MEDISALE, FIDELMED, PHARMA FIDELMED, HEALTH AND BEAUTY SHOP, DYNA DISTRIBUTION

since 2009

Establishments

Establishment units

Physical locations of this company

Registered office

Gistelsesteenweg 18

8400 Oostende

2.389.823.444

Waalkens 11 box b

9030 Gent

Active since 1 June 2026

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

APOTHEEK RAES same network

€ 125,258 gross margin · 2025

DecuDental

€ 367,360 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0817.127.010

VAT number

BE 0817.127.010

Registered office

Gistelsesteenweg 18, 8400 Oostende

Names & denominations

DECURA PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 July 2009

Peppol

Active · Active since 2 Sept 2023

Activities · NACE

Activiteiten van hoofdkantoren

Activiteiten van holdings

Holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

View on CBE Public ↗ Annual accounts (NBB) ↗

DECURA PHARMA

Warning lights

Financials

What happened to DECURA PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions